This week, we will discuss the final results of the NEFIGARD trial with the GFR slope data. Is targeted release budesonide aka Nefecon really a way to provide steroid efficacy without steroid side effects?
This week, we tag along with NephMadness. It will be hard to stay impartial while discussing the role of angiogenic and antiangiogenic factors in severe preeclampsia prognosis.
This week, during kidney month and NephMadness season, we will discuss the USRDS report as well as the ISN Global Kidney Health Atlas report from 2024.
This week, we will discuss the JAMA paper on disparities in living donor kidney transplant *rates* across race/ethnicities. There is a parallel paper from the UK, which shows somewhat similar findings. Join us Feb 6 and 7 to discuss on #NephJC!
How long should we allow metformin to remain the bogeyman in CKD? Should MALA scare us from ever letting our patients benefit from metformin? Join us as we discuss some rare prospective data on metformin in moderate to severe CKD.
Thiazide induced hyponatremia occurs in about 10% of people. Is there a genetic link? Does that genetic link give clues to the mechanism of thiazide induced hyponatremia? Find out in the next exciting edition of #NephJC
This week, we will discuss the fresh-off-the-press NEJM paper on the utility of using NAC (vs placebo) or bicarb-based hydration (vs saline) in preventing contrast AKI. A medical reversal that has taken almost 2 decades...
This week, we will discuss the fresh-off-the-press and fresh from KidneyWk REPRISE trial, which was also presented at the late breaking clinical trial session. Join us to discuss the nitty-gritty on Nov 14th and 15th
Join us this week as we discuss guidelines - with a difference. Hypertension, but in children - as the AAP unveiled them recently. The entire manuscript is over 70 pages, so make sure you read this succinct summary from Cathy Quinlan.
We will be discussing a systematic review on treatment options for uremic pruritis. Such a simple symptom can be so bothersome, and is so common. Join us as we discuss the options on Sep 27
The ACTIVE trial tested the hypothesis that longer dialysis would be better for quality of life. Sadly, this did not turn out to be the case. Is the end of longer being better? Join us as we dissect the study at the next NephJC.
Stop-IgAN suggested steroids may not be useful in patients with intermediate range proteinuria. Now, in a different population with more proteinuria, TESTING finds a mixed result: some benfit + more adverse events. Should we keep on TESTING?
Here it is! The NephJC Summer Book Club returns. In this inaugural post Dr. Grubbs tells the backstory behind the book title and own journey from her initial idea for a book to becoming published author.
This week, we will discuss the fresh-off-the-press ISPD guidelines on encapsulating peritoneal sclerosis. We are happy to have support from the ISPD for organizing this - and making the manuscript open, and also the ISPD Vancouver 2018 team, who will be co-hosting the #NephJC chat.
Were the EMPA-REG Renal results chance, or is this a class effect? Let's take a deep dive into CANVAS, published in the NEJM recently, which examined the cardiovascular safety of canaglifozin in type 2 diabetes.